November 18, 2026
Health news, explained with evidence
LIVE
CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee

FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee

🏥 Public Health 2 min read 👁 0

The White House has withdrawn Heidi Overton’s nomination for FDA commissioner, leaving the agency without a permanent leader and facing significant policy hurdles.

FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee🏥Public Health

Photo: statnews.com

Key points

  • White House withdraws Heidi Overton's FDA commissioner nomination.
  • Agency has lacked permanent leadership since May.
  • FDA faces upcoming challenges regarding drug review funding and global biotech competition.

The White House unexpectedly withdrew the nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday. This decision has created a leadership vacuum at the federal agency, which has lacked a permanent head since May. Currently, acting commissioner Kyle Diamantas is overseeing operations, marking the third leadership transition for the FDA during the current administration.

The agency now faces a period of instability as it prepares to identify a fourth potential nominee. This leadership uncertainty arrives at a critical time, as the FDA must navigate the upcoming reauthorization of user fees that support drug review processes. These legislative negotiations may be further complicated by recent shifts in the political landscape following midterm elections.

Beyond internal staffing, the agency is tasked with addressing evolving scientific and global challenges. Leadership will need to manage the integration of artificial intelligence into research protocols while simultaneously addressing the need to remain competitive with the growing biotechnology sector in China. Please consult with a healthcare professional regarding how federal health policy changes might affect your access to medical products.

What to know: The FDA is currently operating under acting leadership, which may impact the timing of regulatory reviews and long-term policy decisions.

Source statnews.com — statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-a… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.